Review Article: Host Cell Signalling and Mechanisms of Evasion
Review Article: Host Cell Signalling and Mechanisms of Evasion
Review Article: Host Cell Signalling and Mechanisms of Evasion
1155/2012/819512
1. Background
Apart from the impact of Leishmania on world health, Leishmaniasis represents an elegant infection model that can teach us a lot about host-parasite interactions and immune evasion. This parasite has the ability to enter host macrophages (Ms) safely and replicate inside the very same phagocytes that were recruited to destroy it. The inability of Ms to kill the parasite and activate cells of the adaptive immune system is a product of the parasites long-reported capacity to alter several key signalling pathways in the host. Many signalling alterations are seen early in the course of infection suggesting they start upon the initial contact between the parasite and the M. These rapid alterations of signalling pathways serve at least two main functions: rstly, inhibition of M killing mechanisms that are triggered upon phagocytosis of foreign particles (e.g., production of reactive oxygen species), and secondly, inhibition of leishmanicidal functions that can be triggered in response to M activation in infected tissues in response to stimuli such as lipopolysaccharides (LPS) or
interferon- (IFN-) (e.g., nitric oxide production). In this review, we will discuss the roles of Leishmania in disease establishment, focusing on the signalling pathways that they interfere with and the M functions that are aected by the alteration of these pathways.
2 Firstly, protein kinase C (PKC), a protein family comprising 10 serine/threonine kinases, initially characterized as Ca+2 and phospholipid dependent [5, 6], is classied into three subfamilies: the conventional (PKC-, -I, -II, and -), novel (PKC- , -, -, and - ), and atypical (PKC- and -) isoforms [7]. PKC signalling is known to play a key role in the regulation of M functions activating, for instance, cytokines such as IFN- and TNF- [8, 9], both having important roles in driving several M functions including NO production [8] and oxidative burst [10]. Promastigote LPG has been described to be able to block PKC activity [11 13]. This inhibition is achieved through the binding of LPG to the regulatory domain of PKC which contains the DAG, Ca+2 , and phospholipid binding sites [14]. It is interesting to observe that amastigotes, which lack LPG, are also able to inhibit PKC activity in monocytes [15], suggesting that factors other than LPG can also mediate this inhibitory eect. Indeed, Leishmania-induced ceramide generation [16] and GIPLs [12] have been shown to be able to do so, providing a possible mechanism whereby amastigotes can inhibit PKC activity. Later on, Janus kinase 2 (JAK2) as one of four members of the Janus family of tyrosine kinases (JAK1, JAK2, JAK3, and TYK2), has been identied to be importantly aected by Leishmania infection. JAK activation plays an important role in cell proliferation, dierentiation, migration, apoptosis, and immune activation [17]. The JAK signalling pathway is initiated when a cytokine or a growth factor binds to its receptor inducing receptor multimerization followed by JAKs transphosphorylation and activation, ultimately leading to the phosphorylation of signal transducer and activator of transcription (STAT), a transcription factor (TF), that will then dimerize and proceed to nucleus by translocation and to bind target regulatory sequences to activate or repress transcription [17, 18]. Importantly, the iNOS gene promoter responsible for NO production has binding sites for several TFs including STAT1 [19, 20]. Leishmania has the ability to block the JAK/STAT signalling pathway in response to IFN- stimulation, therefore avoiding the induction of NO. Indeed, it has been reported that infection with L. donovani amastigotes was able to block IFN--induced JAK1, JAK2, and STAT-1 phosphorylation in PMA-dierentiated U-937 promonocytic cells and human monocytes [21]. However, we went further in studying the eect of Leishmania on JAK2 phosphorylation by reporting that L. donovani promastigotes were rapidly activating host SHP-1 leading to the subsequent inhibition of IFN--induced JAK2 phosphorylation [22], see Figure 1. Others have suggested that IFN- unresponsiveness to stimulation can be due to the inhibition of the IFN- receptor (IFN-R) complex formation [23], however they did not provide any clues on how the parasite could do so. Another complication with this report is that the authors infected cells for 24 hours to see an appreciable eect on receptor expression and phosphorylation, which cannot explain the rapid dephosphorylation of JAK2 seen when BMDMs are infected with Leishmania promastigotes [22], supporting the notion that early JAK/STAT inhibition must depend on parasite-induced alterations of existing signalling molecules
Journal of Tropical Medicine of the host and not on alterations at the transcriptional level. In the same line of ideas, several members of the mitogen-activated protein kinases (MAPKs) family (e.g., extracellular signal-regulated kinase1/2 (Erk1/2), proline for Jun N-terminal kinase (JNK), and glycine for p38), known to play critical role in the activation of several TFs [24], have been found to be exploited by Leishmania parasite (Figure 1). Indeed, as was the case with the JAK family, it is remarkable, though not unexpected, that the Leishmania parasite developed tactics to render several MAPK members inactive in response to parasite entry to Ms or to activating stimuli that follow infection. For instance, it was reported that the phagocytosis of L. donovani promastigotes by naive Ms does not lead to the activation of any of the three MAPKs (Erk1/2, JNK, p38) [25]. Furthermore, activation of several MAPKs in response to LPS has been shown to be inhibited in infected cells. For instance, L. amazonensis amastigotes are able to block LPS-mediated Erk1 phosphorylation in infected Ms [26], and L. donovani amastigotes can block PMAinduced Erk1/2 phosphorylation in RAW264 Ms leading to the inhibition of Elk-1 and c-fos expression [27]. The authors of the latter study suggested a role for host PTPs in Erk1/2 inactivation, a hypothesis supported and more deeply explored by our laboratory where we provided evidence that PTP-SHP-1 is able to dephosphorylate and inactivate Erk1/2 through demonstrating that this MAPK was still able to be activated in Leishmania-infected SHP-1-decient Ms in response to IFN- stimulation [28]. Alternatively, it has been suggested that ceramide production by L. donovaniinfected Ms can lead to reduce Erk1/2 phosphorylation [29]. Interestingly, amastigotes of L. mexicana were also reported to inhibit Erk1/2 signalling not by inhibiting their phosphorylation, but rather by degrading them using the parasites cysteine proteinases. Similar cysteine proteinasedependent degradation was observed for JNK [30]. In regard to p38, it has been shown that this MAPK is nonresponsive when Ms infected with L. major are stimulated with a CD40 antibody to mimic the M-T cell interaction. p38 inactivation correlated with impaired iNOS2 expression and NO production and therefore impaired leishmanicidal functions [31]. In fact, this inactivation makes sense in the light of experiments showing the importance of p38 activation in the control of Leishmania infection. The use of anisomycin, a p38 activator, enhanced parasite killing in Ms by triggering p38-dependent antileishmanial eects [31, 32]. In order to inhibit gene expression of proinammatory cytokines and microbicidal molecules, Leishmania developed several strategies to interfere with TFs that bind to the promoters of those genes. Several TFs are involved in this process including NF-B, STAT-1, and AP-1, all of which known to be modulated by the parasite. In fact, several groups have reported dierent strategies employed by Leishmania to alter, for instance, the TF NF-B. Leishmania-induced ceramide generation by Ms was shown to play a role in NF-B inhibition [29]. One study provided evidence that L. major amastigotes blocked the nuclear translocation of the p65/p50 complex selectively favouring the c-Rel/p50
01
3/4/2012 by: alok kum.
2 MD
IRAK4
MyD AP TIR 88
Proteosome
m ish Le
IRAK2
IRAK1 gp63
ia an
IF TR
TBK1 IRF-3
TRAF6
IB
SHP-1
PTP-1B
STAT1 STAT1
XXXXXXXXXXX
Figure 1: Downregulation of macrophages signalling by Leishmania infection. Leishmania infection modulates phosphatases (SHP-1 and PTP1B) activity by mechanism involving the metalloprotease gp63. SHP-1 was found to interact with IRAK-1, a key kinase involved on TLRtriggered signaling pathway. Whereas, both SHP-1 and PTP-1B are involved in the downregulation of IFN-induced pathway (JAK/STAT1) as well as MAPK activation. In addition, transcription factor such as NF-B and AP-1 are cleaved/degraded in part by Leishmania gp63. Orange arrows indicate gp63 involved modulation; black arrows indicate activation; red abrogated lines indicate downregulation.
complex that, they proposed, plays a role in the gene expression of immunosuppressive cytokines in Ms such as IL-10 [33]. Another study reported that cysteine proteinases of L. mexicana mediated NF-B degradation and caused its inability to bind its DNA consensus sequence, thus partially explaining how the parasite can inhibit LPS-mediated IL12 production [30]. Work from our laboratory showed that promastigotes of several pathogenic Leishmania species were able to cleave the p65 RelA subunit to generate a p35 RelA fragment translocating to the nucleus and bind DNA. This p35 fragment was suggested to be involved in the parasites ability to drive NF-B-mediated chemokine gene expression in infected Ms [34]. In addition to NF-B and the fact we have previously described Leishmanias ability to inhibit the JAK/STAT pathway [22], our laboratory has also reported that the parasite is able to repress IFN--mediated signalling in Ms by interfering with STATs. We showed that L. donovani promastigotes were able to cause proteasome-mediated STAT-1 degradation in infected Ms. However, whereas STAT-1 degradation was reversed using proteasome inhibitors [35], its capacity to respond to IFN- was still altered due to JAK2 inactivation (unpublished data). AP-1 is a structurally complex TF formed by dimmers from Jun and Fos protein family [36] that can be activated by
many kinds of stimuli such as growth factors, cytokines, hormones, and pathogens, which do so using several signalling molecules. Consequently, the previously mentioned tactics employed by Leishmania to interfere with PKC, Erk1/2, JNK, and p38 activities have a direct impact on the ability of the parasite to block AP-1 signalling in Ms. Importantly, work from our group demonstrated a role for SHP-1 in AP1 inhibition [28, 37] and, more recently, that the parasites surface protease gp63 is responsible for the cleavage and degradation of key AP-1 subunits [38]. The latter nding provides the rst demonstration that a parasite-derived molecule can directly interfere with AP-1 in host Ms in order to block its downstream functions.
JAK1
IFNR
p35
JAK2
AP M K
4 (I/V)HCxxGxxR(S/T), and mediates the hydrolysis via the formation of a thiophosphate intermediate [40]. Receptorlike PTPs include RPTP-, CD45, and CD148, and the function of some like CD45 in immune cell signalling are well known [41]. However, herein we will focus on a selected group of soluble PTPs that have been shown to play a role in Leishmania host evasion mechanisms, namely, PTP-1B, TC-PTP, PTP-PEST, and most importantly SHP-1. PTP-1B and TC (T cell)-PTP: they are two ubiquitously expressed PTPs that have more than 73% identity in their catalytic domain [42]. PTP-1B is known to play important regulatory functions in metabolism, as demonstrated by the insulin hypersensitivity of PTP-1B/ mice and their resistance to high-fat-diet-induced obesity [43, 44]. This insulin hypersensitivity was shown to be due to the ability of PTP-1B to dephosphorylate the insulin receptor [45]. PTP-1B also seems to play a role in the regulation of cytokine signalling through its ability to interact with and dephosphorylate members of the JAK family, namely, JAK2 and TYK2 [46]. In addition to PTP-1Bs role in the regulation of JAK/STAT signalling, a role for this phosphatase in the regulation of TLR4 signalling was proposed. PTP-1B/ Ms had increased LPS-induced iNOS expression and NO production compared to WT Ms and were more susceptible to endotoxic shock following low-dose LPS injection [41]. As PTP-1B was found to be an important negative regulator of Ms signaling, its role in Leishmaniasis could be critical. In fact, we recently showed that Leishmania gp63 was able to enhance PTP-1B activation by cleaving it. PTP-1B activity seems to inhibit M activation and help in parasite survival as seen in the delayed onset of footpad swelling and reduced parasite burden in PTP-1B/ mice infected with L. major [47]. In addition, we found that TC-PTP that also plays important roles in the negative regulation of JAK1, JAK3 [48], and nuclear STAT-1 [49] was modulated by gp63 in Leishmania-infected Ms [47]. This gp63-mediated TCPTP cleavage along with the cleavage of PTP-PEST was recently reported by our group and M.L. Tremblays group to enhance the catalytic activity of the PTPs in question and/or allow them to access additional substrates that might help the parasite establish itself [50]. Another PTP modulated by Leishmania gp63 is SHP-1. This PTP contains two N-terminal SH2 domains (N-SH2, C-SH2), followed by a PTP domain responsible for dephosphorylating substrates, and a C-terminal tail [41]. This phosphatase is mostly expressed in hematopoietic cells [51, 52], but is also expressed at lower levels in epithelial [52], endothelial [53, 54], and central nervous system cells [55]. The SH2 domains have two main functions: rstly, the N-SH2 domain plays an important autoinhibitory role by interacting intramolecularly with the PTP domain, keeping the PTP in the inactive state. Secondly, both SH2 domains have the ability to bind to phosphotyrosine (p-Y) residues usually found within immunoreceptor tyrosine-based inhibitory motifs (ITIMs) whose consensus sequence is (I/V/L/S)xYxx(L/V) [36]. This second feature of SH2-domains is thought to play a role in the detachment of the N-SH2 from the PTP domain once the C-SH2 domain binds to a target p-Y, therefore opening up and activating the PTP [41].
Journal of Tropical Medicine At the signalling level, our laboratory have clearly demonstrated that Leishmania was able to rapidly activate host SHP-1 causing SHP-1-mediated JAK2 inactivation in Ms [22]. Additionally, we and others have implicated SHP-1 in the negative regulation of Erk1/2 activity [27, 28] and in the regulation of the downstream TFs NF-B and AP-1 [28] during Leishmania infection. At the functional level, our laboratory showed that the injection of PTP inhibitors (bpVphen, a bis-peroxovanadium compounds) to mice infected with L. major or L. donovani helped control the infection [56] in a manner dependent on iNOS expression and NO production [57]. Furthermore, we demonstrated that SHP1-decient viable moth-eaten mice infected with L. major did not develop footpad swelling and had signicantly reduced parasitic loads [58]. This decreased pathology was associated with increase activated neutrophil recruitment to the footpad and more iNOS mRNA expression [58]. As to how Leishmania is able to activate SHP-1, it has been proposed that Leishmanias elongation factor-1 (EF1) is responsible for the activation of host SHP-1 seen 16 hours after infection [59]. This report cannot explain, however, how SHP-1 is activated in earlier infection times nor does it explain how EF-1 of the parasite can shuttle from the phagolysosome where the parasite is to the cytosol where SHP-1 is found. A more plausible mechanism has been recently suggested by our group, where SHP-1 was shown to be activated via cleavage by the parasites protease gp63, which gains access to the cytosol by going through the lipid raft of host Ms [47]. Collectively, it appears that the rapid activation of SHP-1 by Leishmania is a key host evasion step whereby the parasite is able to utilize this phosphatase to negatively regulate several key M pathways and render them unresponsive to activating stimuli such as IFN- and LPS. By doing so, the parasite is able to block several M functions such as NO production and the synthesis of many proinammatory cytokines that can be deadly to the parasite if allowed to be produced.
Journal of Tropical Medicine by host immune cells. One study showed that infection of mice with L. major upregulated the gene expression of several chemokines (RANTES/CCL5, MIP-1/CCL3, IP10/CXCL10, and MCP-1/CCL2) in cells collected from the footpad and their draining lymph nodes [60]. Additionally, we have shown that L. major infection caused an upregulation in the expression of several chemokines (RANTES, MIP1, MIP-1/CCL4, IP-10, MCP-1, and MIP-2/CXCL1) in cells being rapidly recruited at the site of inoculation [61]. It is interesting to see that most of these chemokines are monocyte chemoattractants, recruiting Ms to infected tissues and helping the parasite get installed. It is equally interesting to see that none of these chemokines, with the exception of MIP-2, attract neutrophils. This is in accordance with our previous nding that exacerbated neutrophil recruitment to infection sites is associated with parasite killing in SHP-1 decient viable moth-eaten mice [58]. So far, we have considered chemokine upregulation as benecial to the parasite, yet it is important to bear in mind that secreted chemokines during Leishmaniasis can act as a double-edged sword. Whereas selective activation of chemotactic factors can help the parasite to recruit Ms and neutrophils that they can infect and/or utilize during the initial step of infection, treatment of susceptible BALB/c with recombinant IP-10 in the early course of L. major infection has been shown to increase NK cell cytotoxic activity in the draining lymph nodes and to drive a healing IFN--mediated Th1 response [62]. In chronic infections, chemokine types, amounts, and duration of chemotactic eect have been implicated in parasite clearance or persistence. For instance, in visceral Leishmaniasis, clearance of parasites from the liver is strongly associated with increased late phase IP-10 production and the Th1 eects associated with its presence [62]. Parasite persistence in the spleen, on the other hand, has been correlated with sustained MCP-1, but not IP-10 levels [63]. Whereas Leishmania can modulate selected chemokines, importantly the inhibition of key microbicidal functions is crucial for its initial survival. For instance, one of the dangers that Leishmania encounters recruiting and entering Ms is the ability of these cells to produce deadly free radicals such as NO [64] and reactive oxygen intermediates (ROIs) [65]. NO is produced by NOS which converts one of the terminal nitrogens of the guanidino group of L-arginine to NO producing L-citrulline [66, 67]. The importance of this free radical in Leishmaniasis was demonstrated by several groups. An early study showed the ability of activated Ms to kill L. major amastigotes by an L-arginine-dependent mechanism [68]. Later conrmed by the observation that L-N-monomethyl arginine (L-NMMA), an L-arginine analogue and inhibitor of the NO pathway was able to inhibit the leishmanicidal eect of Ms activated in vitro with IFN- or LPS. They also showed the ability of NO in cell-free suspensions to kill the parasite. Importantly, the same group demonstrated the importance of NO in vivo by rendering resistant CBA mice susceptible to L. major infection upon local administration of L-NMMA [64]. However, parasite is able to block its synthesis in response to stimuli such as IFN- [69], but how can Leishmania
5 achieve this inhibition? A critical role for host SHP-1 has been proposed. As previously stated, Leishmania has the ability to rapidly activate SHP-1 in infected Ms and by doing so can interfere with several molecules involved in NO production including JAK2, Erk1/2, and the TFs NFB and AP-1. Indeed, SHP-1 decient Ms infected with L. donovani are still able to produce NO in response to IFN- stimulation, unlike infected WT Ms which are refractory to a similar stimulation [28]. As expected, the IFN-mediated NO production in infected SHP-1 decient Ms correlated with successful JAK2 and Erk1/2 phosphorylation and the activation of NF-B and AP-1. These ndings further elucidate the role of SHP-1 activation in parasite survival and propagation through its ability to contribute to NO inhibition [28]. Another mechanism involved in the downregulation of NO production is by conversion of arginine to ornithine and urea via the arginase pathway [70]. Supporting this mechanism, recently, it has been shown that arginase as well as polyamines gene expression are upregulated by L. amazonensis amastigote [71]. Whereas those latter mechanisms of evasion are to be of general use by all, Leishmania parasite will need further investigation. In addition to NO, ROIs represent another source of danger to Leishmania. These intermediates include the superoxide radical and hydrogen peroxide produced by cells of the immune system such as neutrophils and Ms in response to various agonists. Although important in parasite killing, the activity of the respiratory burst in mice was shown to have an early and transient eect only. This conclusion is based on the delayed granuloma formation and resolution of infection seen in respiratory burst-decient X-CGD mice infected with L. donovani compared to WT [72]. Despite the critical role that NO seems to play in Leishmania killing [72], ROIs do contribute to parasite clearance and are therefore a target to be inhibited by the parasite. Indeed, L. donovani has been shown to inhibit the oxidative burst in infected Ms [15, 73, 74], and this inhibition was in part mediated by the parasite surface molecules LPG and gp63 [14, 75] involving PKC inactivation [15]. Interestingly, it was later shown that LPG of L. donovani promastigotes is able to block NADPH oxidase assembly at the phagosome membrane without interfering with p47(phox) phosphorylation and its ability to form complexes with p67(phox) [76]. L. donovani amastigotes, on the other hand, were shown to eectively block superoxide release through inhibiting the phosphorylation of the NADPH oxidase component p47(phox), leading to defective recruitment of p47(phox) and p67(phox) to the phagosome [77]. The inhibition of p47(phox) phosphorylation could be a result of the previously reported ability of Leishmania amastigotes to inhibit PKC activity [15], which is reported to be required for p47(phox) phosphorylation [78]. Downregulation of ROIs seems also to be modulated by ERK as inhibitor of ERK decreased ROIs production, increasing the killing of L. amazonensis amastigote, however this mechanism is not applied to all species as L. major still survives [79]. In addition to those nitrous and oxygen derivatives, IL-1 and TNF- have been correlated with antimicrobial activities against bacteria and parasites in vitro and in vivo [8083],
6 and IL-12 is well known for its ability to promote Th1 dierentiation and to activate NK cells [84]. In regard to IL-1 and TNF-, it has been shown that these molecules are not produced upon a 12 h in vitro infection of human monocytes with L. donovani amastigotes [85]. Interestingly, preinfection of those cells diminished LPS-mediated IL-1 production, but not IL-1 m-RNA, suggesting inhibition at the translational level [85]. Another study showed that preincubation of human monocytes with puried LPG was able to cause inhibition of LPS-mediated IL-1 secretion [86]. The role of LPG in IL-1 inhibition was later shown to involve LPG ability to inhibit IL-1 gene transcription in a manner dependent on the nucleotide region 310 to 57 of the promoter region [87]. This inhibitory eect of LPG on IL-1 gene transcription was suggested to involve an inhibition of the binding of an activation factor or an induction of an unknown transcription repressor [87]. Interestingly, a study by our laboratory revealed that SHP-1 decient mice infected with L. major produced signicantly higher amounts of IL-1 and TNF- compared to their littermates [61], suggesting that Leishmania-induced SHP-1 activity could play a pivotal role in the attenuation of the inammatory response repressing the proinammatory cytokines production. IL-12 is another key cytokine inhibited by Leishmania. This inhibitory eect is necessary for parasite survival given the established role of this molecule in driving Th1 differentiation and production of IFN- by T cells and NK cells, which in turn can activate Ms to kill the parasite. It has been reported that infection of BMDMs with promastigotes of L. major or L. donovani fails to induce IL-12 production, both following infection alone and upon subsequent LPS or heat-killed bacterial stimulation of Ms [88]. Similar observations were seen when murine Ms were infected with amastigotes of L. major and L. mexicana [89]. Furthermore, incubation of activated murine Ms with LPG led to the inhibition of IL-12 production by these cells, with the inhibition occurring at the transcriptional level [90]. The mechanism by which IL-12 is inhibited by Leishmania remains not fully understood. Roles for the M CR3 [91] and Fc-R [92] have been proposed. Recently, we have reported a very interesting mechanism whereby Leishmania can inhibit LPS-mediated proinammatory functions such as IL-12 and TNF- production. We showed that Leishmania-induced SHP-1 is able to bind to an evolutionarily conserved immunoreceptor tyrosine-based inhibitory motif (ITIM)-like motif (which we renamed kinase tyrosine-based inhibitory motif (KTIM)) found in the kinase domain of IL-1 receptor-associated kinase 1 (IRAK-1), causing its inactivation. SHP-1-bound IRAK-1 is no longer able to detach from Myeloid dierentiation factor 88 (MyD88) to bind TNF receptor-associated factor 6 (TRAF6) and activate downstream signalling pathways, therefore explaining in part how the parasite is able to block LPS-mediated MyD88dependent proinammatory functions in host macrophages [93]. One remarkable tactic the parasite utilizes to subvert the immune response is its ability to inhibit IFN--induced MHC class II expression in infected Ms. Indeed,
Journal of Tropical Medicine L. chagasi and L. donovani were both shown to inhibit MHC II expression in response to IFN- stimulation [9496]. Surprisingly, Ms infected with L. major or L. amazonensis showed normal phagocytosis, Ag processing, and MHC II production, yet these cells failed to present parasitic Ags to Tcell hybridomas [97, 98]. Authors of both studies concluded that the failure to present Ags to T cells is due to the parasites ability to interfere with the loading of Ags onto MHC II molecules. Another interesting mechanism to control Ag presentation is shown by amastigotes of L. amazonensis being able to internalize MHC II molecules and to degrade them using their cysteine proteinases [99]. Activation of CD4+ T cells involves a two-signal model whereby two signals are required to activate the T helper cell. The rst signal is triggered by the binding of the T-cell receptor (TCR) to the MHC II-Ag complex on the APC, and the second is provided by the binding of CD28 or CD40L on T cells to costimulatory molecules of APCs such as those of the B7 family or CD40. Interestingly, apart from interfering with the rst signal by inhibiting MHC II presentation, Leishmania has been demonstrated to interfere with M costimulatory signals. L. donovani infection was reported to block LPS-mediated B7-1 expression in infected Ms [100], a mechanism that seems to be mediated by prostaglandins [101]. Furthermore, L. major was reported to interfere with CD40 signalling in infected Ms in a p38-dependent manner [31]. This result is very interesting, especially because previous studies have established a protective role for CD40 in Leishmania major infections [102, 103], while others have reported that the disruption of CD40/CD40L ligation results in increased susceptibility to L. amazonensis infection [104]. The increased susceptibility caused by the disruption of CD40/CD40L ligation was in part due to the inhibition of iNOS expression [102, 104] and IL-12 production [105] by infected Ms. So far, we have discussed several mechanisms by which Leishmania can interfere with key signalling pathways involved in M activation such as the JAK/STAT pathway. We also discussed alterations that occur to signalling molecules involved in TLR signalling such as MAPKs and the TFs NFB and AP-1. However, this does not give justice to TLR signalling, given its extremely important role in the activation of APCs to kill invading pathogens and/or activate cells of the adaptive immune system. Equally important are the strategies developed by pathogens to block TLR signalling pathways that can lead to undesirable activation of immune functions. Therefore, the last portion of this review will discuss TLR signalling and how Leishmania parasite deals with this important group of pathogen sensors.
Journal of Tropical Medicine to detect parasites and eliminate them when favourable conditions are present. Second, the ability of parasites to counteract TLR detection by interfering with TLR signalling keeping immune cells in an inactive state and rendering them refractory to subsequent TLR stimulation. One of the main parasite-derived molecules involved in TLR binding and activation is GPI-anchored proteins. Trypanosoma cruzi-derived GPI-anchors were shown to be detected by TLR2/TLR6 and CD14 and to activate NF-B [106, 107], while GIPLs of T. cruzi activated Chinese hamster ovary (CHO) cells in a TLR4/CD14-dependent manner [108]. It has been also shown that GPI-mucin of T. cruzi is able to activate TLR signalling on rst exposure and induce tolerance to secondary TLR stimulation [109]. This was later shown to be mediated by the ability of GPI-mucin to induce the expression and activation of the serine/threonine phosphatase PP2A that acts on cellular IRAK-1, MAPKs, and IB causing their inhibition and leading to tolerance [110]. The induction of PP2A was shown to require p38 and NF-B, the very same molecules PP2A is induced to inhibit, therefore giving rise to an autoregulatory loop [110]. LPG of Leishmania is another GPI-anchored protein detected by TLRs. It has been shown that LPG of L. major directly binds to TLR2 of Ms and NK cells [111, 112] and that LPG of L. donovani is also detected by TLR2 of activated Ms [113]. Interestingly, GPI-anchors derived from Plasmodium falciparum merozoites can induce TNF production in human monocytes and mouse Ms through interacting with TLR1/TLR2 and to a lesser extent TLR4 [114, 115]. Moreover, GPI- anchors of Toxoplasma gondii are detected by TLR2 and TLR4, which can thus play an important role in host defense against T. gondii infections [116]. Although less numerous than GPI-anchored ligands, non-GPI-related ligands represent an important group of parasite-related molecules detected by TLRs. An example is the T. cruzi-derived protein Tc52, which is able to induce proinammatory cytokine production in DCs in a TLR2dependent manner [117]. Other important non-GPI ligands include the DNA of T. cruzi, T. brucei, and Babesia bovis, which are able to activate Ms and DCs [118, 119], possibly through unmethylated CpG motifs [120] detected by TLR9 [121, 122]. TLR3 was recently shown to be upregulated in IFN--primed Ms and to play a role in their leishmanicidal activity. The silencing of TLR3 led to impaired NO and TNF- production in IFN--primed Ms in response to L. donovani infection and increased parasite survival [113]. Given that the only known ligand of TLR3 is dsRNA, the parasite component that activates TLR3 remains unclear. The authors ruled out the presence of dsRNA Leishmania virus infection in their parasite strain and also failed to detect natural Leishmania-derived double-stranded RNA structures such as rRNA or tRNA [113]. As far as apicomplexans are concerned, Plasmodium-derived hemozoin crystals were shown to induce proinammatory cytokines in Ms [123, 124]. Initially, TLR9 was proposed as the binding receptor of hemozoin [125], this remains controversial as it has been later shown that TLR9 activation by hemozoin is mediated by malaria DNA attached to the crystal and that the activation of TLR9 by hemozoin was abolished upon treatment with
7 nucleases [126]. In fact, recent data from our laboratory show that the proinammatory cytokine IL-1 is induced by hemozoin through the Nod-like receptor family, pyrin domain containing 3 protein (NLRP3), and the adaptor protein Asc, which lead to caspase 1 activation [127]. Concerning Toxoplasma, a prolin-like protein from T. gondii (PFTG) activates TLR11 in mouse cells [128], and heat shock proteins and partially puried preparations isolated from tachyzoites activate TLR4 and TLR2, respectively [129, 130]. The many parasite-related molecules that are detected by TLRs suggest an important role for TLR-related signalling molecules in the resistance to parasitic infections [131]. Given the fact that Th1-driving proinammatory responses are benecial to the host in several types of parasitic infections, it is not surprising that the activation of the MyD88-dependent pathway is crucial in the resistance to many protozoan diseases. Indeed, MyD88-decient mice are highly susceptible to T. cruzi [132], T. brucei [122], L. major [133], and T. gondii [134] infections due to the decreased inammatory response and the impaired production of Th1associated cytokines such as IL-12 and IFN- in these mice. It is important to mention that MyD88-driven proinammatory events are not always favourable to the host in the ght against protozoans. The decreased inammatory and Th1 responses in MyD88-decient mice were seen to improve pathology and outcome of P. berghei infection in mice. This suggests that Plasmodium, in this case, utilizes the MyD88dependent pathway to cause tissue injury and worsen disease symptoms [135]. It is quite remarkable that the amount of susceptibility to several protozoan infections conferred by the absence of MyD88 is signicantly higher than that observed when mice lacking a single TLR are used. This strongly suggests that several TLRs are simultaneously involved in the recognition of parasites, thus explaining why the loss of MyD88 can have a bigger impact on susceptibility compared to the loss of a single TLR [131]. Nevertheless, deciency of relevant TLRs increases susceptibility to certain infections. For example, TLR9-decient mice have higher parasitemia and mortality when infected with T. cruzi [121] or T. brucei [122]. TLR4decient mice are more susceptible to L. major infection with bigger lesion size and parasite loads compared to WT mice [136, 137], and TLR11-decient mice are more susceptible to T. gondii infection manifesting increased cyst formation in the central nervous system and decreased IL-12 and IFN- production compared to WT mice [128]. The ability of TLRs to detect parasite PAMPs put together with the fact that many successful infections are associated with silent entry to target cells suggests that parasites must have evasion tactics to block TLR signalling and functions. Some of these mechanisms have been already described, while others are still to be discovered. We will hereby discuss some evasion strategies employed by Leishmania, Plasmodium, and Toxoplasma. The ability of Leishmania to interfere with TLR signalling components has been already discussed in this chapter under the signalling pathways altered by Leishmania section. These evasion mechanisms include the previously discussed ability of the parasite to interfere with the activation of all
8 three MAPKs (Erk1/2, JNK, and p38) (see MAPK section) and its ability to interfere with IB, NF-B, and AP-1 (see TF section). There is also evidence that signalling through CR1 and CR3, which Leishmania is known to bind to, can inhibit LPS- and IFN--induced IL-12 production through impaired STAT-1 phosphorylation [91]. A similar role for Fc-R ligation has been proposed [92, 138]. Nevertheless, very little is known about how the parasite can interfere with critical upstream proteins unique to IL-1/TLR signalling such as members of the IRAK family. Our laboratory has been interested for many years in exploring mechanisms utilized by Leishmania to block TLR signalling in Ms, and to evaluate the role of host SHP-1 in this process (Figure 1). Of utmost interest, we have recently established SHP-1 as a central regulator of TLR signalling which can be exploited by Leishmania to inhibit IRAK-1 leading to the inability of Ms to respond to a wide range of TLR ligand stimulation including LPS, favoring parasite survival [93]. Other pathogen evasion tactics include the ability of P. falciparum to cause infected erythrocytes to express P. falciparum erythrocyte membrane protein 1 (PfEMP1) which was shown to interact with the scavenger receptor CD36 on the surface of DCs [139] making the cells that phagocytose these infected erythrocytes become unresponsive to LPS stimulation, ultimately leading to defects in T-cell activation [140142]. T. gondii is yet another parasite able to block LPSmediated IL-12 and TNF- production, the upregulation of costimulatory molecules, and the activation of T cells [143 146]. One way the parasite is able to do so is by activating STAT3 in IL-10-dependent and -independent manners [147, 148]. Although this T. gondii-induced inhibition of subsequent LPS stimulation might somehow resemble LPS tolerance in that it inhibits MAPKs like p38 [149], important dierences between infection and LPS tolerance exist. Unlike LPS tolerance, T. gondii infection followed by LPS stimulation resulted in the activation of MKK3 and MKK6 (upstream activators of p38) and in the degradation of IB [149]. This suggests that the inactivation of p38 observed when LPS stimulation is preceded by Toxoplasma infection is either due to the inhibition of another p38-activating kinase such as MKK4 or is mediated by a T. gondii-induced MAPK phosphatase that prevents the phosphorylation-dependent activation of p38 [131]. It is interesting to note that although T. gondii infection followed by LPS stimulation causes IB activation, the liberated NF-B fails to translocate to the nucleus [150, 151]. Later studies suggested that the lack of NF-B translocation might actually be due to increased nuclear export of this TF rather than inhibition of nuclear import [152]. Collectively, it is clear that TLRs play a crucial role in mounting innate and adaptive immunity against invading pathogens. Alteration of TLR signalling by pathogens or by clinical drugs can play a key role in the outcome of infections. We have discussed in good detail strategies used by pathogens or by the clinic to alter TLR signalling. The activation of MyD88-dependent signalling and Th1 responses can turn out very useful in the elimination of many pathogens including Leishmania. However, these eorts must always
Journal of Tropical Medicine be perceived with caution as exaggerated activation of inammation can cause edema, pain, and tissue injury and in severe conditions could be deadly. In addition, certain infectious models like malaria seem to benet from MyD88dependent signalling and inammation in their pathology, and thus a completely dierent approach should be used when trying to ght Plasmodium. As opposed to using TLR ligands which can worsen the disease, TLR agonists could prove clinically eective in treating malaria. Nevertheless, the eects of blocking TLR-TLR-L interactions on the ability of the immune system to ght o other pathogens that can be/become present have to be taken into serious consideration.
6. Concluding Remarks
Over the last 15 years, research stemming from our laboratory and others has provided strong evidence that parasites of the Leishmania genus are able to establish themselves and to propagate within the mammalian host due to its ability to alter key signalling pathways, therefore interfering with the induction of critical M functions that can otherwise threaten parasite survival. Importantly, we have identied one key way Leishmania can do so, and this is by exploiting host negative regulatory mechanisms such as the modulation of M PTPs.
References
[1] W. Harnett, M. R. Deehan, K. M. Houston, and M. M. Harnett, Immunomodulatory properties of a phosphorylcholine-containing secreted larial glycoprotein, Parasite Immunology, vol. 21, no. 12, pp. 601608, 1999. [2] S. D. Tachado, R. Mazhari-Tabrizi, and L. Schoeld, Specicity in signal transduction among glycosylphosphatidylinositols of Plasmodium falciparum, Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp, Parasite Immunology, vol. 21, no. 12, pp. 609617, 1999. [3] S. Haque, H. Dumon, A. Haque, and L. H. Kasper, Alteration of intracellular calcium ux and impairment of nuclear factor-AT translocation in T cells during acute Toxoplasma gondii infection in mice, The Journal of Immunology, vol. 161, no. 12, pp. 68126818, 1998. [4] M. Olivier, D. J. Gregory, and G. Forget, Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view, Clinical Microbiology Reviews, vol. 18, no. 2, pp. 293305, 2005. [5] Y. Takai, A. Kihsimoto, M. Inoue, and Y. Nishizuka, Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. I. Purication and characterization of an active enzyme from bovine cerebellum, The Journal of Biological Chemistry, vol. 252, no. 21, pp. 7603 7609, 1977. [6] M. Inoue, A. Kishimoto, Y. Takai, and Y. Nishizuka, Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. II. Proenzyme and its activation by calcium-dependent protease from rat brain, The Journal of Biological Chemistry, vol. 252, no. 21, pp. 7610 7616, 1977. [7] M. E. Reyland, Protein kinase C isoforms: multi-functional regulators of cell life and death, Frontiers in Bioscience, vol. 14, pp. 23862399, 2009.
9
impaired IFN--triggered JAK2 activation, European Journal of Immunology, vol. 29, no. 11, pp. 37373744, 1999. M. Ray, A. A. Gam, R. A. Boykins, and R. T. Kenney, Inhibition of interferon- signaling by Leishmania donovani, Journal of Infectious Diseases, vol. 181, no. 3, pp. 11211128, 2000. S. Boldt and W. Kolch, Targeting MAPK signalling: prometheus re or pandoras box? Current Pharmaceutical Design, vol. 10, no. 16, pp. 18851905, 2004. C. Priv e and A. Descoteaux, Leishmania donovani promastigotes evade the activation of mitogen-activated protein kinases p38, c-Jun N-terminal kinase, and extracellular signal-regulated kinase-1/2 during infection of naive macrophages, European Journal of Immunology, vol. 30, no. 8, pp. 22352244, 2000. A. Martiny, J. R. Meyer-Fernandes, W. De Souza, and M. A. Vannier-Santos, Altered tyrosine phosphorylation of ERK1 MAP kinase and other macrophage molecules caused by Leishmania amastigotes, Molecular and Biochemical Parasitology, vol. 102, no. 1, pp. 112, 1999. D. Nandan, R. Lo, and N. E. Reiner, Activation of phosphotyrosine phosphatase activity attenuates mitogen- activated protein kinase signaling and inhibits c-FOS and nitric oxide synthase expression in macrophages infected with Leishmania donovani, Infection and Immunity, vol. 67, no. 8, pp. 40554063, 1999. G. Forget, D. J. Gregory, L. A. Whitcombe, and M. Olivier, Role of host protein tyrosine phosphatase SHP-1 in Leishmania donovani-induced inhibition of nitric oxide production, Infection and Immunity, vol. 74, no. 11, pp. 62726279, 2006. S. Ghosh, S. Bhattacharyya, M. Sirkar et al., Leishmania donovani suppresses activated protein 1 and NF-B activation in host macrophages via ceramide generation: involvement of extracellular signal-regulated kinase, Infection and Immunity, vol. 70, no. 12, pp. 68286838, 2002. P. Cameron, A. McGachy, M. Anderson et al., Inhibition of lipopolysaccharide-induced macrophage IL-12 production by Leishmania mexicana amastigotes: the role of cysteine peptidases and the NF-B signaling pathway, The Journal of Immunology, vol. 173, no. 5, pp. 32973304, 2004. A. Awasthi, R. Mathur, A. Khan et al., CD40 signaling is impaired in L. major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response, Journal of Experimental Medicine, vol. 197, no. 8, pp. 10371043, 2003. M. Junghae and J. G. Raynes, Activation of p38 mitogenactivated protein kinase attenuates Leishmania donovani infection in macrophages, Infection and Immunity, vol. 70, no. 9, pp. 50265035, 2002. L. Guizani-Tabbane, K. Ben-Aissa, M. Belghith, A. Sassi, and K. Dellagi, Leishmania major amastigotes induce p50/cRel NF-B transcription factor in human macrophages: involvement in cytokine synthesis, Infection and Immunity, vol. 72, no. 5, pp. 25822589, 2004. D. J. Gregory, M. Godbout, I. Contreras, G. Forget, and M. Olivier, A novel form of NF-B is induced by Leishmania infection: involvement in macrophage gene expression, European Journal of Immunology, vol. 38, no. 4, pp. 10711081, 2008. G. Forget, D. J. Gregory, and M. Olivier, Proteasomemediated degradation of STAT1 following infection of macrophages with Leishmania donovani, The Journal of Biological Chemistry, vol. 280, no. 34, pp. 3054230549, 2005.
[23]
[24]
[25]
[26]
[27]
[28]
[29]
[30]
[31]
[32]
[33]
[34]
[35]
10
[36] J. V. Ravetch and L. L. Lanier, Immune inhibitory receptors, Science, vol. 290, no. 5489, pp. 8489, 2000. [37] J. Blanchette, I. Abu-Dayyeh, K. Hassani, L. Whitcombe, and M. Olivier, Regulation of macrophage nitric oxide production by the protein tyrosine phosphatase Src homology 2 domain phosphotyrosine phosphatase 1 (SHP-1), Immunology, vol. 127, no. 1, pp. 123133, 2009. [38] I. Contreras, M. A. Gomez, O. Nguyen, M. T. Shio, R. W. McMaster, and M. Olivier, Leishmania-induced inactivation of the macrophage transcription Factor AP-1 Is Mediated by the Parasite Metalloprotease GP63, PLoS Pathogens, vol. 6, no. 10, Article ID e1001148, 2010. [39] M. Larsen, M. L. Tremblay, and K. M. Yamada, Phosphatases in cell-matrix adhesion and migration, Nature Reviews Molecular Cell Biology, vol. 4, no. 9, pp. 700711, 2003. [40] J. M. Denu and J. E. Dixon, Protein tyrosine phosphatases: mechanisms of catalysis and regulation, Current Opinion in Chemical Biology, vol. 2, no. 5, pp. 633641, 1998. [41] L. I. Pao, K. Badour, K. A. Siminovitch, and B. G. Neel, Nonreceptor protein-tyrosine phosphatases in immune cell signaling, Annual Review of Immunology, vol. 25, pp. 473523, 2007. [42] A. Bourdeau, N. Dub e, and M. L. Tremblay, Cytoplasmic protein tyrosine phosphatases, regulation and function: the roles of PTP1B and TC-PTP, Current Opinion in Cell Biology, vol. 17, no. 2, pp. 203209, 2005. [43] M. Elchebly, P. Payette, E. Michaliszyn et al., Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene, Science, vol. 283, no. 5407, pp. 15441548, 1999. [44] L. D. Klaman, O. Boss, O. D. Peroni et al., Increased energy expenditure, decreased adiposity, and tissue-specic insulin sensitivity in protein-tyrosine phosphatase 1B-decient mice, Molecular and Cellular Biology, vol. 20, no. 15, pp. 54795489, 2000. [45] M. Elchebly, A. Cheng, and M. L. Tremblay, Modulation of insulin signaling by protein tyrosine phosphatases, Journal of Molecular Medicine, vol. 78, no. 9, pp. 473482, 2000. [46] M. P. Myers, J. N. Andersen, A. Cheng et al., TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B, The Journal of Biological Chemistry, vol. 276, no. 51, pp. 47771 47774, 2001. [47] M. A. Gomez, I. Contreras, M. Hall e, M. L. Tremblay, R. W. McMaster, and M. Olivier, Leishmania GP63 alters host signaling through cleavage-activated protein tyrosine phosphatases, Science Signaling, vol. 2, no. 90, article ra58, 2009. [48] P. D. Simoncic, A. Lee-Loy, D. L. Barber, M. L. Tremblay, and C. J. McGlade, The T cell protein tyrosine phosphatase is a negative regulator of Janus family kinases 1 and 3, Current Biology, vol. 12, no. 6, pp. 446453, 2002. [49] J. Ten Hoeve, M. D. J. Ibarra-Sanchez, Y. Fu et al., Identication of a nuclear Stat1 protein tyrosine phosphatase, Molecular and Cellular Biology, vol. 22, no. 16, pp. 56625668, 2002. [50] M. Hall e, M. A. Gomez, M. Stuible et al., The Leishmania surface protease GP63 cleaves multiple intracellular proteins and actively participates in p38mitogen-activated protein kinase inactivation, The Journal of Biological Chemistry, vol. 284, no. 11, pp. 68936908, 2009. [51] R. J. Matthews, D. B. Bowne, E. Flores, and M. L. Thomas, Characterization of hematopoietic intracellular protein tyrosine phosphatases: description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic
[52]
[53]
[54]
[55]
[56]
[57]
[58]
[59]
[60]
[61]
[62]
[63]
[64]
[65]
11
[80] E. H. De Titto, J. R. Catterall, and J. S. Remington, Activity of recombinant tumor necrosis factor on Toxoplasma gondii and Trypanosoma cruzi, The Journal of Immunology, vol. 137, no. 4, pp. 13421345, 1986. [81] C. J. Czuprynski, J. F. Brown, K. M. Young, A. J. Cooley, and R. S. Kurtz, Eects of murine recombinant interleukin 1 on the host response to bacterial infection, The Journal of Immunology, vol. 140, no. 3, pp. 962968, 1988. [82] L. E. M. Bermudez and L. S. Young, Tumor necrosis factor, alone or in combination with IL-2, but not IFN-, is associated with macrophage killing of Mycobacterium avium complex, The Journal of Immunology, vol. 140, no. 9, pp. 3006 3013, 1988. [83] Y. Ozaki, T. Ohashi, A. Minami, and S. I. Nakamura, Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1a, Infection and Immunity, vol. 55, no. 6, pp. 14361440, 1987. [84] M. Del Vecchio, E. Bajetta, S. Canova et al., Interleukin-12: biological properties and clinical application, Clinical Cancer Research, vol. 13, no. 16, pp. 46774685, 2007. [85] N. E. Reiner, W. Ng, C. B. Wilson, W. R. McMaster, and S. K. Burchett, Modulation of in vitro monocyte cytokine responses to Leishmania donovani. Interferon- prevents parasite-induced inhibition of interleukin 1 production and primes monocytes to respond to Leishmania by producing both tumor necrosis factor- and interleukin 1, The Journal of Clinical Investigation, vol. 85, no. 6, pp. 19141924, 1990. [86] S. Frankenburg, V. Leibovici, N. Mansbach, S. J. Turco, and G. Rosen, Eect of glycolipids of Leishmania parasites on human monocyte activity. Inhibition by lipophosphoglycan, The Journal of Immunology, vol. 145, no. 12, pp. 42844289, 1990. [87] D. E. Hatzigeorgiou, J. Geng, B. Zhu et al., Lipophosphoglycan from Leishmania suppresses agonist-induced interleukin 1 gene expression in human monocytes via a unique promoter sequence, Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 25, pp. 1470814713, 1996. [88] L. Carrera, R. T. Gazzinelli, R. Badolato et al., Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice, Journal of Experimental Medicine, vol. 183, no. 2, pp. 515526, 1996. [89] N. Weinheber, M. Wolfram, D. Harbecke, and T. Aebischer, Phagocytosis of Leishmania mexicana amastigotes by macrophages leads to a sustained suppression of IL-12 production, European Journal of Immunology, vol. 28, no. 8, pp. 24672477, 1998. [90] D. Piedrata, L. Proudfoot, A. V. Nikolaev et al., Regulation of macrophage IL-12 synthesis by leishmania phosphoglycans, European Journal of Immunology, vol. 29, no. 1, pp. 235244, 1999. [91] T. Marth and B. L. Kelsall, Regulation of interleukin-12 by complement receptor 3 signaling, Journal of Experimental Medicine, vol. 185, no. 11, pp. 19871995, 1997. [92] F. S. Sutterwala, G. J. Noel, R. Clynes, and D. M. Mosser, Selective suppression of interleukin-12 induction after macrophage receptor ligation, Journal of Experimental Medicine, vol. 185, no. 11, pp. 19771985, 1997. [93] I. Abu-Dayyeh, M. T. Shio, S. Sato, S. Akira, B. Cousineau, and M. Olivier, Leishmania-induced IRAK-1 inactivation is mediated by SHP-1 interacting with an evolutionarily conserved KTIM motif, PLoS Neglected Tropical Diseases, vol. 2, no. 12, article e305, 2008.
12
[94] M. C. De Almeida, S. A. Cardoso, and M. Barral-Netto, Leishmania (Leishmania) chagasi infection alters the expression of cell adhesion and costimulatory molecules on human monocyte and macrophage, International Journal for Parasitology, vol. 33, no. 2, pp. 153162, 2003. [95] N. E. Reiner, W. Ng, and W. R. McMaster, Parasite-accessory cell interactions in murine leishmaniasis. II. Leishmania donovani suppresses macrophage expression of class I and class II major histocompatibility complex gene products, The Journal of Immunology, vol. 138, no. 6, pp. 19261932, 1987. [96] N. E. Reiner, W. Ng, T. Ma, and W. R. McMaster, Kinetics of interferon binding and induction of major histocompatibility complex class II mRNA in Leishmania-infected macrophages, Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 12, pp. 43304334, 1988. [97] U. Fruth, N. Solioz, and J. A. Louis, Leishmania major interferes with antigen presentation by infected macrophages, The Journal of Immunology, vol. 150, no. 5, pp. 18571864, 1993. [98] E. Prina, C. Jouanne, S. De Souza Lao, A. Szabo, J. G. Guillet, and J. C. Antoine, Antigen presentation capacity of murine macrophages infected with Leishmania amazonensis amastigotes, The Journal of Immunology, vol. 151, no. 4, pp. 20502061, 1993. [99] S. De Souza Leao, T. Lang, E. Prina, R. Hellio, and J. C. Antoine, Intracellular Leishmania amazonensis amastigotes internalize and degrade MHC class II molecules of their host cells, Journal of Cell Science, vol. 108, no. 10, pp. 32193231, 1995. [100] P. M. Kaye, N. J. Rogers, A. J. Curry, and J. C. Scott, Decient expression of co-stimulatory molecules on Leishmaniainfected macrophages, European Journal of Immunology, vol. 24, no. 11, pp. 28502854, 1994. [101] B. Saha, G. Das, H. Vohra, N. K. Ganguly, and G. C. Mishra, Macrophage-T cell interaction in experimental visceral leishmaniasis: failure to express costimulatory molecules on Leishmania-infected macrophages and its implication in the suppression of cell-mediated immunity, European Journal of Immunology, vol. 25, no. 9, pp. 24922498, 1995. [102] M. Kamanaka, P. Yu, T. Yasui et al., Protective role of CD40 in Leishmania major infection at two distinct phases of cellmediated immunity, Immunity, vol. 4, no. 3, pp. 275281, 1996. [103] K. A. Campbell, P. J. Ovendale, M. K. Kennedy, W. C. Fanslow, S. G. Reed, and C. R. Maliszewski, CD40 ligand is required for protective cell-mediated immunity to Leishmania major, Immunity, vol. 4, no. 3, pp. 283289, 1996. [104] L. Soong, J. C. Xu, I. S. Grewal et al., Disruption of CD40CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection, Immunity, vol. 4, no. 3, pp. 263273, 1996. [105] F. P. Heinzel, R. M. Rerko, and A. M. Hujer, Underproduction of interleukin-12 in susceptible mice during progressive leishmaniasis is due to decreased CD40 activity, Cellular Immunology, vol. 184, no. 2, pp. 129142, 1998. [106] M. A. S. Campos, I. C. Almeida, O. Takeuchi et al., Activation of toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite, The Journal of Immunology, vol. 167, no. 1, pp. 416423, 2001. [107] C. Ropert and R. T. Gazzinelli, Regulatory role of toll-like receptor 2 during infection with Trypanosoma cruzi, Journal of Endotoxin Research, vol. 10, no. 6, pp. 425430, 2004.
13
infection and regulates parasite-induced IL-12 production by dendritic cells, The Journal of Immunology, vol. 168, no. 12, pp. 59976001, 2002. K. Adachi, H. Tsutsui, S. I. Kashiwamura et al., Plasmodium berghei infection in mice induces liver injury by an IL12- and toll-like receptor/myeloid dierentiation factor 88dependent mechanism, The Journal of Immunology, vol. 167, no. 10, pp. 59285934, 2001. P. Kropf, M. A. Freudenberg, M. Modolell et al., Tolllike receptor 4 contributes to ecient control of infection with the protozoan parasite leishmania major, Infection and Immunity, vol. 72, no. 4, pp. 19201928, 2004. P. Kropf, N. Freudenberg, C. Kalis et al., Infection of C57BL/10ScCr and C57BL/10ScNCr mice with Leishmania major reveals a role for Toll-like receptor 4 in the control of parasite replication, Journal of Leukocyte Biology, vol. 76, no. 1, pp. 4857, 2004. M. Grazia Cappiello, F. S. Sutterwala, G. Trinchieri, D. M. Mosser, and X. Ma, Suppression of IL-12 transcription in macrophages following Fc receptor ligation, The Journal of Immunology, vol. 166, no. 7, pp. 44984506, 2001. B. C. Urban, N. Willcox, and D. J. Roberts, A role for CD36 in the regulation of dendritic cell function, Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 15, pp. 87508755, 2001. C. Oca na-Morgner, M. M. Mota, and A. Rodriguez, Malaria blood stage suppression of liver stage immunity by dendritic cells, Journal of Experimental Medicine, vol. 197, no. 2, pp. 143151, 2003. J. A. Perry, C. S. Olver, R. C. Burnett, and A. C. Avery, Cutting edge: the acquisition of TLR tolerance during malaria infection impacts T cell activation, The Journal of Immunology, vol. 174, no. 10, pp. 59215925, 2005. B. C. Urban, D. J. P. Ferguson, A. Pain et al., Plasmodium falciparuminfected erythrocytes modulate the maturation of dendritic cells, Nature, vol. 400, no. 6739, pp. 7377, 1999. B. A. Butcher and E. Y. Denkers, Mechanism of entry determines the ability of Toxoplasma gondii to inhibit macrophage proinammatory cytokine production, Infection and Immunity, vol. 70, no. 9, pp. 52165224, 2002. E. Y. Denkers, L. Kim, and B. A. Butcher, In the belly of the beast: subversion of macrophage proinammatory signalling cascades during Toxoplasma gondii infection, Cellular Microbiology, vol. 5, no. 2, pp. 7583, 2003. A. S. McKee, F. Dzierszinski, M. Boes, D. S. Roos, and E. J. Pearce, Functional inactivation of immature dendritic cells by the intracellular parasite Toxoplasma gondii, The Journal of Immunology, vol. 173, no. 4, pp. 26322640, 2004. S. Bennouna, W. Sukhumavasi, and E. Y. Denkers, Toxoplasma gondii inhibits toll-like receptor 4 ligand-induced mobilization of intracellular tumor necrosis factor alpha to the surface of mouse peritoneal neutrophils, Infection and Immunity, vol. 74, no. 7, pp. 42744281, 2006. L. Williams, L. Bradley, A. Smith, and B. Foxwell, Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inammatory eects of IL-10 in human macrophages, The Journal of Immunology, vol. 172, no. 1, pp. 567576, 2004. B. A. Butcher, L. Kim, A. D. Panopoulos, S. S. Watowich, P. J. Murray, and E. Y. Denkers, Cutting edge: IL-10-independent STAT3 activation by Toxoplasma gondii mediates suppression of IL-12 and TNF- in host macrophages, The Journal of Immunology, vol. 174, no. 6, pp. 31483152, 2005.
[135]
[136]
[137]
[138]
[139]
[140]
[141]
[142]
[143]
[144]
[145]
[146]
[147]
[148]
14
[149] L. Kim, B. A. Butcher, and E. Y. Denkers, Toxoplasma gondii interferes with lipopolysaccharide-induced mitogen-activated protein kinase activation by mechanisms distinct from endotoxin tolerance, The Journal of Immunology, vol. 172, no. 5, pp. 30033010, 2004. [150] B. A. Butcher, L. Kim, P. F. Johnson, and E. Y. Denkers, Toxoplasma gondii tachyzoites inhibit proinammatory cytokine induction in infected macrophages by preventing nuclear translocation of the transcription factor NF-B, The Journal of Immunology, vol. 167, no. 4, pp. 21932201, 2001. [151] S. Shapira, K. Speirs, A. Gerstein, J. Caamano, and C. A. Hunter, Suppression of NF-B activation by infection with Toxoplasma gondii, Journal of Infectious Diseases, vol. 185, no. 1, pp. S66S72, 2002. [152] S. Shapira, O. S. Harb, J. Margarit et al., Initiation and termination of NF-B signaling by the intracellular protozoan parasite Toxoplasma gondii, Journal of Cell Science, vol. 118, no. 15, pp. 35013508, 2005.
Annotations
Page no. 2
Infecting host system, particularly cell lines or macrophages for a few hours actually provides the best system to see the alteration into the cell signalling events.If we infect the cells for a longer time period then certain events are unnoticed